Introduction
Toxoplasma gondii is an obligate intracellular protozoan that infects humans worldwide. After allo-SCT, patients with Toxoplasma infection may sporadically develop toxoplasmosis disease, primarily because of reactivation of the latent infection. Rarely, they may be infected after transplantation through blood or leukocyte transfusions or by ingesting contaminated food or water. 1 The incidence of toxoplasmosis after allo-SCT varies from 0.1 to 6.0%. [2] [3] [4] [5] [6] [7] European and Latin American case series report an incidence of 1-6%, [2] [3] [4] 6 whereas the United States and Japan report incidences of o0.5%. 5, 7, 8 These differences reflect the great variation in seroprevalence in populations around the world (from o10% to 490%), related mainly to diet and hygiene habits. 1 The seroprevalence of toxoplasmosis among US-born persons declined from 14.1 to 9.0% between the periods of 1988-1994 and 1999-2004 . 9 In the United States, risk factors for toxoplasmosis infection include eating raw meat and mollusks, working with meat, drinking unpasteurized goat's milk, and being exposed to kittens. 10 In countries with a high incidence of infection, much progress has been made in the early detection of toxoplasmosis after allo-SCT, with serial screening of peripheral blood for Toxoplasma DNA using PCR; preemptive therapy is used in patients with positive PCR results. 3, 11 The new guidelines for prevention of infection among SCT recipients recommend prophylaxis and/or PCR screening of patients at a high risk of toxoplasmosis but do not define clearly who is at risk and the period of time for the intervention. 12 Even with effective therapy for toxoplasmosis, mortality among SCT recipients is 60-90%, 2,4,13 compared with o30% in patients with AIDS. 4 
Patients and methods
We used ICD-9 codes and the pathology laboratory database at High-dose corticosteroid use was defined as treatment with X1 mg/kg/day of methylprednisolone or equivalent and continuation of corticosteroids for X14 days and until onset of toxoplasmosis, regardless of dose adjustment.
Results

Patients
We identified 9 patients who had been diagnosed with toxoplasmosis (Table 1 ) among 3626 allo-SCT recipients at our institution from 1994 to 2009, an incidence of 0.25%. The incidence was higher among the 246 international patients (1.6%) than among the 3380 US patients (0.15%) (P ¼ 0.002). Most of our international patients came from Latin America or the Middle East.
Eight patients had definite infections, and one had a probable infection (patient 9). Six patients had received grafts from matched related donors, one had received a graft from a matched unrelated donor, and two had received T-cell-depleted mismatched grafts from relatives. Baseline Toxoplasma immunoglobulin G levels were not routinely determined before transplantation. Three (33%) Toxoplasmosis in allo-SCT VE Mulanovich et al patients developed toxoplasmosis despite being on trimethoprim/sulfamethoxazole prophylaxis (one doublestrength tablet given twice weekly BID), although treatment adherence could not be assessed. All patients were lymphopenic (absolute lymphocyte count o500 cells/mL) at the time of diagnosis. The median time from SCT to the onset of symptoms was 64 days (range, 0-237 days). Patients 
Clinical presentation
Three patients had disseminated or pulmonary toxoplasmosis. Toxoplasmosis was diagnosed postmortem in patients 1 and 8. Both patients had been febrile and developed pneumonia and sepsis, followed by multi-organ failure and death; neither had received active treatment for Toxoplasma infection. Patient 9 became febrile and developed bilateral infiltrates after transplantation; this patient did not experience a response to broad-spectrum anti-bacterial, anti-fungal, or anti-viral therapy. She had repeatedly positive Toxoplasma DNA PCR results, first reported on day 6 of fever, and defervesced promptly on clindamycin, pyrimethamine, and leucovorin, with resolution of infiltrates and fever and negative Toxoplasma PCR results. She completed 12 weeks of therapy and received atovaquone as secondary prophylaxis.
The remaining six patients presented with neurologic symptoms of 6 days' median duration and were found to have ring-enhancing lesions on brain magnetic resonance imaging that were suspicious for central nervous system toxoplasmosis. The diagnosis was confirmed by biopsy in four cases, autopsy in one, and CSF cytological examination in one (Figure 1 ). CSF Toxoplasma DNA PCR results were positive in two patients and negative in one. All six patients had undergone specific treatment for toxoplasmosis, initiated a median of 4 days after presentation (range, 1-16 days); only one experienced a resolution. The median duration of treatment in the five patients who did not experience a response was 4 weeks (range, 2-8 weeks), whereas the one who experienced a response received treatment for 10 weeks and died of Gram-negative pneumonia while completing treatment. Treatment regimens included (1) pyrimethamine with trimethoprim/ sulfamethoxazole, (2) pyrimethamine with sulfadiazine, (3) pyrimethamine with clindamycin, and (4) trimethoprim/sulfamethoxazole.
Co-morbidities and outcomes
Nineteen co-morbid conditions (other than underlying disease, recent transplantation, and GVHD) were identified in seven patients (Table 1) . Fifteen were infections-four viral, eight bacterial, and two fungal-and one patient had active tuberculosis. In addition, two had diffuse alveolar hemorrhage, one had a severe gastrointestinal bleed, and one experienced graft failure. In two patients, no co-morbid conditions were identified.
Of the two patients who experienced resolution of toxoplasmosis (22%), one was alive at last follow-up and one had died of Gram-negative pneumonia while completing treatment for toxoplasmosis. Of the remaining seven patients, one died of central nervous system toxoplasmosis, and six (67%) died of toxoplasmosis and other co-morbid conditions.
Discussion
The incidence of toxoplasmosis after allo-SCT in our patients was 0.25%, which is consistent with the results of prior US reports. 7, 8 International patients at our hospital, who were mostly from Latin America or the Middle East, had a significantly higher incidence of toxoplasmosis than did US patients. Immigrants from high seroprevalence countries may be at similar risk. The true incidence is likely higher, as lack of suspicion, difficult diagnosis, and low autopsy rates all contribute to lower it. Two European prospective studies that followed seropositive patients post allo-SCT using serial Toxoplasma PCR reported a 6-month incidence of toxoplasmosis of 6%, higher than retrospective studies.
3,11
We did not perform pre-transplantation Toxoplasma serologic tests in our patients. Assuming a Toxoplasma seroprevalence of 9% in our 3380 US patients, 9 we would expect 304 seropositive patients, with a toxoplasmosis incidence of 1.6%, similar to that in our international patients. We recommend testing all allo-SCT candidates for Toxoplasma IgG positivity to determine the true seroprevalence, which may be quite different, and also to determine who is at risk of reactivation, as pre-transplantation Toxoplasma serologic screening results have been found to be positive in 88-94% of reported cases of Toxoplasmosis in allo-SCT VE Mulanovich et al toxoplasmosis, and reactivation is the most likely mechanism of disease after allo-SCT. 4, 13 One-third of the patients in our study developed toxoplasmosis early (within the first 30 days after transplantation). Early toxoplasmosis was previously reported in 13-14% of cases and 20% of autopsy-diagnosed cases. 4, 13 The remaining two-thirds became symptomatic during the first 100 days after the initiation of high-dose corticosteroids. Corticosteroid use varied greatly, with numerous dose changes over time; nevertheless, all patients were receiving corticosteroids at symptom onset.
Toxoplasmosis in allo-SCT patients has a high mortality rate-60-90% in most case series.
2,4,13 Our patients had a mortality rate of 89%. In seven patients, treatment was started early (median of 4 days after symptom onset) and continued for at least 2 weeks, yet only one patient survived. The exclusion of possible cases and patients' multiple severe co-morbidities may account for the high mortality rate in this study despite early and adequate treatment. Martino et al. 4 reported concomitant severe infections in 40% of patients and Mele et al. 13 in 38%. The role of co-morbidities should be more closely studied and accounted for when comparing outcomes in different transplantation centers and is a reflection of the degree of immunosuppression.
International and US seropositive patients are at high risk for toxoplasmosis and may account for an estimated 20% of our allo-SCT patients, although the true seroprevalence in our population has not been determined; these patients can be targeted for focused interventions, in particular during high-risk periods: the first month after SCT and after the initiation of high-dose corticosteroids. Preemptive therapy guided by weekly testing of peripheral blood for Toxoplasma DNA by PCR has been shown to be effective. 3, 11 Alternatively, prophylaxis with weekly pyrimethamine/sulfadoxine was found to be effective at preventing toxoplasmosis and pneumocystosis, with acceptable and reversible hematologic toxicities, in a study by Foot et al. 14 Adherence to prophylaxis is difficult because of side effects, polypharmacy, and toxicities.
We recommend that Toxoplasma PCR in peripheral blood should be part of the workup of febrile Toxoplasma seropositive allo-SCT patients. In addition, high suspicion for toxoplasmosis, early initiation of empiric anti-Toxoplasma therapy, and appropriate diagnostic studies are needed for transplantation patients with unexplained central nervous system or pulmonary symptoms or sepsis because cases have been reported with negative Toxoplasma DNA PCR results or with the development of symptoms at the same time of the first positive PCR result.
3,11 PCR techniques for detection of T. gondii are not standardized and there is no consensus in the optimal protocol to be used in clinical laboratories. 11 Validation of in-house tests, reproducibility, and quality controls are required.
The strengths of our study are the inclusion of only definite and probable cases of toxoplasmosis, and the careful study of co-morbidities and corticosteroid use in our patients. The small number of patients from a single institution and retrospective nature of this study are its main limitations.
In summary, toxoplasmosis is a rare but life-threatening complication of allo-SCT. In the United States and other countries of low seroprevalence, high-risk patients include those from high-endemicity countries and those who are seropositive. All allo-SCT candidates should be screened for Toxoplasma IgG seropositivity. The use of high-dose corticosteroids for GVHD and other indications often precedes 'late' cases (patients who present more than 30 days after SCT). These patients can be targeted for preemptive therapy, guided by regular screening with blood Toxoplasma DNA PCR, or the use of prophylactic therapy. Toxoplasma DNA PCR in peripheral blood should be obtained in seropositive febrile allo-SCT patients, and empiric therapy considered when sepsis, neurologic, or pulmonary signs and symptoms occur, as toxoplasmosis cases with negative Toxoplasma DNA PCR results have been described.
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